Secondary Prevention of Esophageal Variceal Bleeding Is Often Imperfect: A National, Population-Based Cohort Study of 3592 Patients

Clin Gastroenterol Hepatol. 2023 Dec;21(13):3336-3345.e2. doi: 10.1016/j.cgh.2023.05.003. Epub 2023 May 14.

Abstract

Background and aims: Secondary prevention of esophageal variceal bleeding is important to improve prognosis, but uptake of guidelines is unknown in a real-world setting. Here, we determined the proportion of patients receiving appropriate nonselective beta-blocker treatment and repeat upper endoscopy after a first episode of esophageal variceal bleeding within a reasonable time frame.

Methods: Population-based registers were used to identify all patients with a first episode of esophageal variceal bleeding in Sweden from 2006 to 2020. Crosslinkage between registers was performed to receive information on the cumulative incidence of patients with a dispensation of nonselective beta-blockers and repeat upper endoscopy within 120 days from baseline. Overall mortality was investigated using Cox regression.

Results: In total, 3592 patients were identified, with a median age of 63 (interquartile range, 54-71) years. The cumulative incidence of a dispensation of nonselective beta-blockers and a repeat endoscopy within 120 days was 33%. A total of 77% received either of these treatments. Overall mortality was high, with 65% of patients dying after esophageal variceal bleeding during the full follow-up period (median 1.7 years). We observed an improved overall mortality during the later years of the study period (adjusted hazard ratio for the 2016-2020 period compared with the 2006-2010 period, 0.80; 95% confidence interval, 0.71-0.89). Patients with receipt of nonselective beta-blockers and repeat upper endoscopy had better overall survival compared with those without (adjusted hazard ratio, 0.80; 95% confidence interval, 0.72-0.90).

Conclusions: Secondary prevention of esophageal variceal bleeding has not been widely undertaken, with many patients not receiving guideline-supported interventions within a reasonable time frame. This highlights a need to raise awareness on appropriate prevention strategies to clinicians and patients.

Keywords: Beta-Blockade; Cirrhosis; Endoscopy; Epidemiology; Quality of Care; Variceal Bleeding.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aged
  • Cohort Studies
  • Endoscopy, Gastrointestinal / adverse effects
  • Esophageal and Gastric Varices* / complications
  • Esophageal and Gastric Varices* / epidemiology
  • Gastrointestinal Hemorrhage* / epidemiology
  • Gastrointestinal Hemorrhage* / etiology
  • Gastrointestinal Hemorrhage* / prevention & control
  • Humans
  • Ligation / adverse effects
  • Liver Cirrhosis / complications
  • Middle Aged
  • Secondary Prevention

Substances

  • Adrenergic beta-Antagonists